The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite...

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immunotherapy offers a novel treatment for colorectal cancer (CRC), but its effectiveness varies.
• Immune checkpoint molecules (ICMs) are key targets for immunotherapy.
• Understanding ICM expression patterns is crucial for optimizing CRC treatment.

Purpose of the Study:

• To investigate immune checkpoint molecule (ICM) expression patterns in colorectal cancer (CRC).
• To determine differences in ICM expression based on microsatellite instability (MSI) status.
• To explore the potential of combination immunotherapy in CRC.

Main Methods:

• Immunohistochemistry was used to assess programmed cell death protein 1 (PD-1), PD-L1, TIM-3, and LAG-3 expression.
• Tumor samples from 83 non-metastatic CRC patients (40 microsatellite-stable [MSS] and 43 microsatellite-instability-high [MSI-H]) were analyzed.
• Expression was evaluated in both tumor center and periphery.

Main Results:

• PD-L1 and TIM-3 expression were significantly higher in the tumor center of MSI-H CRC patients compared to MSS patients.
• Concomitant expression of two or more ICMs was more frequent than single or no expression in both MSS and MSI-H groups.
• MSI-H CRC patients exhibited higher overall ICM expression levels, with frequent co-expression of multiple ICMs.

Conclusions:

• Microsatellite-instability-high (MSI-H) colorectal cancer (CRC) patients display distinct immune checkpoint molecule (ICM) expression profiles.
• The frequent co-expression of multiple ICMs in MSI-H CRC suggests potential benefit from dual-blockade immunotherapy strategies.
• These findings support further investigation into combination immunotherapy for specific CRC patient subgroups.